Reik & CO. LLC Sells 535 Shares of Johnson & Johnson (NYSE:JNJ)

Reik & CO. LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.3% in the fourth quarter, Holdings Channel reports. The firm owned 15,479 shares of the company’s stock after selling 535 shares during the quarter. Johnson & Johnson comprises about 0.7% of Reik & CO. LLC’s portfolio, making the stock its 18th biggest holding. Reik & CO. LLC’s holdings in Johnson & Johnson were worth $2,426,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. 4J Wealth Management LLC boosted its position in shares of Johnson & Johnson by 2.2% during the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after purchasing an additional 62 shares in the last quarter. My Personal CFO LLC boosted its position in shares of Johnson & Johnson by 1.4% during the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock worth $713,000 after purchasing an additional 62 shares in the last quarter. FIDELIS iM LLC boosted its position in shares of Johnson & Johnson by 3.1% during the fourth quarter. FIDELIS iM LLC now owns 2,117 shares of the company’s stock worth $374,000 after purchasing an additional 64 shares in the last quarter. Clearview Wealth Advisors LLC boosted its position in shares of Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock worth $685,000 after purchasing an additional 64 shares in the last quarter. Finally, Brookmont Capital Management boosted its position in shares of Johnson & Johnson by 0.4% during the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock worth $2,328,000 after purchasing an additional 64 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on JNJ. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, March 13th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Raymond James boosted their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 24th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $177.31.

Johnson & Johnson Stock Down 0.9 %

Shares of JNJ stock opened at $147.52 on Monday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97. The firm’s fifty day moving average price is $157.24 and its two-hundred day moving average price is $155.97. The firm has a market capitalization of $355.49 billion, a P/E ratio of 10.68, a PEG ratio of 2.48 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. Johnson & Johnson’s revenue for the quarter was down 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $2.35 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.